Immunotherapy (DBCOND0038441)

Identifiers

Synonyms
Immunotherapy (procedure)

Associated Data

Indicated Drugs and Targets
DrugDescriptionTargets
Ambrosia artemisiifolia pollen
An extract from Ambrosia artemisiifolia pollen used in allergy testing.
No drug targets
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT06608160
68Ga-grazytracer PET Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer.No drug interventionsNot AvailableNot Availablerecruiting
NCT05848011
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancertreatment2recruiting
NCT06061276
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCCtreatmentNot Availablerecruiting
NCT06510660
Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCCtreatment2recruiting
NCT06586307
Estimating Lymphocyte Counts from DNA MethylationNo drug interventionsNot AvailableNot Availablecompleted
NCT06600841
Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancertreatment2not_yet_recruiting
NCT06603402
Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCCNo drug interventionstreatment2recruiting
NCT04999943
Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic SyndromeNo drug interventionsprevention1recruiting
NCT04057703
Balance Benefit / Risk of Immunomodulatory Treatments at the Child and Adolescent for Autoimmune Cytopenia.No drug interventionsNot AvailableNot Availablecompleted
NCT04500990
MRI DWI None-Gaussian Model Predicting Early Response to Immunotherapy in Digestive System Malignancies: a Prospective Observational StudyNo drug interventionsNot AvailableNot Availableunknown_status
NCT04329221
Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipientsprevention2not_yet_recruiting
NCT05176002
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.treatment1 / 2unknown_status
NCT04641884
Bullous Pemphigoid Induced by antiPD-1/PDL-1 TherapyNo drug interventionsNot AvailableNot Availableunknown_status
NCT04558684
Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal CancerNo drug interventionstreatment1 / 2suspended
NCT05935579
Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancertreatment2recruiting
NCT04642287
Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipientstreatment2not_yet_recruiting
NCT06446154
FOLFOX Chemotherapy Plus Fruquintinib and Sintilimab After First-line Treatment in Unresectable Hepatocellular Carcinomatreatment2not_yet_recruiting
NCT04848454
Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapytreatment2recruiting
NCT04670445
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced CancerNo drug interventionshealth_services_researchNot Availableactive_not_recruiting
NCT04156698
Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinomatreatment2active_not_recruiting
NCT06232083
Application of PLDR External Irradiation Combined With Immune Checkpoint Inhibitors in Recurrent Cervical CancerNo drug interventionstreatment1 / 2recruiting
NCT04570683
Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomastreatment0unknown_status
NCT05310383
Tislelizumab and Radiotherapy for Recurrent Cervical Cancertreatment2unknown_status
NCT06035328
Comparison Efficacy Between Two Different Frequency of Maintenance Dose Oral ImmunotherapyNo drug interventionstreatmentNot Availablerecruiting
NCT05807893
Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastasestreatment2 / 3not_yet_recruiting
NCT04929093
Novel Dose Adjustment Schedule for Late Injection in SCIT in ARNo drug interventionstreatment4completed
NCT04821778
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancertreatment3recruiting
NCT05223088
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancertreatment2recruiting
NCT06241807
Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLCtreatment2recruiting
NCT05621707
Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)No drug interventionstreatment2not_yet_recruiting
NCT03701607
Effect of Chemotherapy on PD-L1 in NSCLCNo drug interventionsNot AvailableNot Availableunknown_status
NCT04670107
The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapytreatment1 / 2completed
NCT04026737
Cardiovascular Effects of CART Cell TherapyNo drug interventionsNot AvailableNot Availablecompleted
NCT05216237
A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancertreatment2recruiting
NCT03003637
ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinomatreatment1 / 2completed
NCT04372732
Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLCNo drug interventionsNot AvailableNot Availableunknown_status
NCT04231552
Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancertreatment1 / 2unknown_status
NCT06165900
Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBCtreatment2recruiting
NCT04387500
Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinomatreatment2active_not_recruiting
NCT05862259
A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced MalignanciesNo drug interventionsNot AvailableNot Availablerecruiting
NCT04397575
The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer PatientsNo drug interventionsNot AvailableNot Availablecompleted
NCT04136470
BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and DiagnosticsNot AvailableNot Availableunknown_status
NCT04465942
Immunotherapy in Lung Cancer: Treatment After IO Cessation.Not AvailableNot Availablerecruiting
NCT06307249
Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNAtreatment1recruiting
NCT06523049
Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapytreatment2not_yet_recruiting
NCT06012318
Dynamic Follow-up of Symptoms Based on Patient-reported Outcomes in Immunotherapy for Esophageal Cancer: a Prospective Multicentre Cohort Study (SPRING)No drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT04286841
The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in ChinaNo drug interventionsNot AvailableNot Availablerecruiting
NCT05375734
Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinomatreatment2recruiting
NCT05982834
Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGCtreatment1 / 2recruiting
NCT06500234
Nutrition Impact on Immunotherapy of Cancertreatment3recruiting
NCT04441424
Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) PatientstreatmentNot Availablecompleted
NCT06573424
Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRCNot AvailableNot Availablerecruiting
NCT06506396
Rehabilitation Needs for Hematologic Cancer Candidate for Hematopoietic Stem Cell Transplantation or CAR T-Cell TherapyNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT06542796
Study on the Classification of Comprehensive Treatment Effect of Hepatocellular CarcinomaNo drug interventionsscreeningNot Availablenot_yet_recruiting
NCT05515796
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumorstreatment2recruiting
NCT06571396
Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular CarcinomaNo drug interventionsNot AvailableNot Availablerecruiting
NCT06128863
Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trialtreatment2recruiting
NCT03589339
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapytreatment1recruiting
NCT04720339
Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy.No drug interventionsotherNot Availablerecruiting
NCT04278222
Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)treatment2recruiting
NCT04890522
An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPCtreatment2 / 3not_yet_recruiting
NCT04552522
Immunological Response After Shrimp Oral Immunotherapy TreatmentNo drug interventionstreatmentNot Availableactive_not_recruiting
NCT04711330
Response and Toxicity Prediction by Microbiome Analysis After Concurrent ChemoradiotherapyNo drug interventionsNot AvailableNot Availableunknown_status
NCT05667857
Longitudinal Neurocognitive, Psychosocial and Health-related Quality of Life Assessment in Advanced Cancer Survivors Treated With Immunotherapy and the Efficacy of Integrative Neurocognitive Remediation TherapyNo drug interventionssupportive_careNot Availablerecruiting
NCT03695757
Development of a New Immunotherapy Using Intramuscular Administration of Autologous Total IgGtreatment1 / 2completed
NCT03693326
PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalitiestreatment2unknown_status
NCT06241326
Immunotherapy for Hepatocellular CarcinomaNo drug interventionsNot AvailableNot Availablerecruiting
NCT04821765
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancertreatment2unknown_status
NCT05476965
Selected De-escalation Radiotherapy for Postoperative Head and Neck Squamous Cell CarcinomaNo drug interventionstreatment2unknown_status
NCT03741231
18FDG-PET in Patients With Melanoma or NSCLC Treated With ImmunotherapyNo drug interventionsNot AvailableNot Availablecompleted
NCT00720031
Treatment of Metastatic Melanoma With Autologous Melan-A/MART-1 Specific CTL ClonesNo drug interventionstreatment1 / 2completed
NCT05273827
Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative DeliriumNot AvailableNot Availablecompleted
NCT02692976
Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer PatientsNo drug interventionstreatment2completed
NCT04188860
Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapytreatment2completed
NCT06125262
Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in ESCC.No drug interventionsNot AvailableNot Availablerecruiting
NCT06302062
Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumorstreatment1recruiting
NCT05637580
Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLCNo drug interventionsNot AvailableNot Availablecompleted
NCT04969029
Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 MutationsNo drug interventionstreatment2recruiting
NCT04291092
Camrelizumab Combined With Local Treatment in NSCLC Patients With BMtreatment2unknown_status
NCT06065592
Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphismsprevention1recruiting
NCT05225844
An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinaltreatment2unknown_status
NCT05817201
Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategytreatment2 / 3recruiting
NCT04688801
Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction CancerNo drug interventionstreatmentNot Availablerecruiting
NCT05833672
Neoadjuvant Immunotherapy in Locally Advanced Colon CancersNo drug interventionstreatment2not_yet_recruiting
NCT06014372
Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancertreatment2recruiting
NCT05161572
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancertreatment2recruiting
NCT03198546
GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 ExpressionNo drug interventionstreatment1recruiting
NCT05266846
Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALKtreatment2recruiting
NCT05967910
The Effect of Chronic Stress on Efficacy of ICIs in Esophageal Cancer Patients (STRESS-ESCA Study)No drug interventionsNot AvailableNot Availablerecruiting
NCT06202781
Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and ChemotherapyNo drug interventionsNot AvailableNot Availablerecruiting
NCT06381895
The Efficacy of Radiomics to Predict Tumor Microenvironment Markers and Comprehensive Therapy for Bladder CancerNo drug interventionsNot AvailableNot Availablecompleted
NCT04921995
Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinomatreatment2unknown_status
NCT03898895
COmbination of Radiotherapy With Anti-PD-1 Antibody for unREseCtable Biliary Tract CancerNo drug interventionstreatment2recruiting
NCT05273255
Fecal Microbiota Transplantation in Patients With Malignancies Not Responding to Cancer ImmunotherapyotherNot Availablerecruiting
NCT05417750
A Phase I Study on Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) for the Treatment of Advanced Malignant Solid TumorsNo drug interventionstreatment1recruiting
NCT03888638
The Role of Tumor-associated Macrophages in Colorectal Liver MetastasesNo drug interventionsNot AvailableNot Availablecompleted
NCT04821843
Neoadjuvant Treatment Modalities in Esophageal Cancertreatment3recruiting
NCT06391190
Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancertreatment1 / 2recruiting
NCT04225390
Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapytreatment2unknown_status
NCT05596890
Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patientstreatment2recruiting
NCT03765190
Combination of Proton Therapy With Immunotherapy in Multiple Metastases CancerNo drug interventionstreatment1 / 2unknown_status
NCT04225364
Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinomatreatment2completed
NCT04389684
Clinical and Psycho-social Impact of COVID-19 Related Confinement on Patients With Digestive TumorsNo drug interventionsNot AvailableNot Availablecompleted
NCT06356584
Sintilimab Combined With Fruquintinib/Regorafenib ± Radiotherapy for Third-line Treatment of Advanced Metastatic Colorectal Cancertreatment2recruiting
NCT05901584
Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLChealth_services_research2recruiting
NCT05215379
Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal CancerNo drug interventionstreatment2 / 3recruiting
NCT03764787
Combination of Hypofractionated Proton Therapy With ImmunotherapyNo drug interventionstreatment1 / 2unknown_status
NCT06037733
Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and ChemotherapyNo drug interventionspreventionNot Availablerecruiting
NCT03619954
NK Cells Infusion for Advanced Malignanciestreatment1unknown_status
NCT04969354
Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell CarcinomaNo drug interventionstreatment1recruiting
NCT06410651
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinomatreatment2recruiting
NCT04521153
Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinomatreatment2 / 3active_not_recruiting
NCT06215677
Neoadjuvant Immunotherapy for T4 dMMR Colon CancertreatmentNot Availablerecruiting
NCT04706598
Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatmenttreatment1 / 2active_not_recruiting
NCT06490198
Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cisplatintreatment1not_yet_recruiting
NCT05913583
Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft RejectionNo drug interventionsNot AvailableNot Availablerecruiting
NCT03357861
Cancer Patients Treated With Immunotherapy in Intensive Care UnitNo drug interventionsNot AvailableNot Availablecompleted
NCT03070561
Evaluating Peanut Immunotherapy Dissolving Film in Healthy SubjectsNo drug interventionsother0completed
NCT04957511
Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving ImmunotherapyNo drug interventionsNot AvailableNot Availablerecruiting
NCT04110093
Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancertreatment1 / 2unknown_status
NCT06134193
Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancertreatment2not_yet_recruiting
NCT03067493
RFA or Surgical Resection Combined With Neo-MASCT for Primary HCC: a Phase II TrialNo drug interventionstreatment2unknown_status
NCT05613478
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinomatreatment3recruiting
NCT04993378
Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid BiopsyNo drug interventionsNot AvailableNot Availableunknown_status
NCT06276088
Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of ImmunotherapyNo drug interventionsNot AvailableNot Availablerecruiting
NCT01475188
Regulatory Lymphocytes in Patients Treated With Specific ImmunotherapyNo drug interventionsbasic_science4completed
NCT04586088
Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failuretreatment2active_not_recruiting
NCT03683407
Effect of Chemotherapy on TMB in NSCLCNo drug interventionsNot AvailableNot Availableunknown_status
NCT03042156
Immunotherapy And Palliative Radiotherapy Combined In Patients With Advanced MalignancyNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT05621356
Monitoring Allergen Immunotherapy in Allergic RhinitisNo drug interventionsNot AvailableNot Availablerecruiting
NCT04895137
mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRCtreatment2recruiting
NCT05909137
Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung CancerNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT04181632
Evaluation of Pain Alleviating Strategies During Allergy ShotsNo drug interventionsotherNot Availablecompleted
NCT04145232
AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.Not AvailableNot Availableunknown_status
NCT04722952
PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine,Cytarabine, G-CSF for Refractory or Relapsed AMLtreatment3unknown_status
NCT03198052
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against CancersNo drug interventionstreatment1recruiting
NCT04547452
Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCCtreatment2unknown_status
NCT05683652
The Effect of Education and Telephone Follow-up Given to Cancer Patients Receiving Immunotherapy on Symptom Management and Self-care PowerNo drug interventionspreventionNot Availableunknown_status
NCT05740800
Patient Care Needs and the Decision-Making Experience of Patients With Cancer and Family Caregivers Regarding Immunotherapy: A Qualitative and Quantitative Mixed Methods StudyNo drug interventionsNot AvailableNot Availablecompleted
NCT06567600
Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinomatreatment2not_yet_recruiting
NCT04539600
Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancertreatment2unknown_status
NCT05354375
Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate CancerNo drug interventionstreatment1recruiting
NCT03580070
Changes in the Microenvironment of HPV-induced Head and Neck Cancers in West Indies and Metropolitan PopulationNo drug interventionsNot AvailableNot Availablecompleted
NCT06413342
Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinomatreatment2recruiting
NCT04805099
Checkpoint Inhibitors in Patients With Cancer and Underlying Autoimmune DiseaseNo drug interventionsNot AvailableNot Availablecompleted
NCT05334849
Prospectively Predict the Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 BiopsyNo drug interventionsNot AvailableNot Availablecompleted
NCT06461936
Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in HCCNot AvailableNot Availableactive_not_recruiting
NCT06070636
bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular CarcinomatreatmentNot Availablerecruiting
NCT04271813
Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)treatment2completed
NCT06065813
Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancertreatment2recruiting
NCT05813418
Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) TreatmentNo drug interventionsotherNot Availablerecruiting
NCT04127318
Low-moderate Intensity Pedaling During Immunotherapy AdministrationNo drug interventionstreatmentNot Availablewithdrawn
NCT04169841
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatmenttreatment2active_not_recruiting
NCT04587817
Combination of Hyperfractionated Radiotherapy With Immunotherapy in Massive TumorsNot AvailableNot Availableunknown_status
NCT05719324
Checkpoint Inhibitors in Patients With Solid Tumors: a Retrospective Real-world StudyNo drug interventionsNot AvailableNot Availablerecruiting
NCT06256224
Toripalimab Combined With Definitive CCRT for LACC PatientstreatmentNot Availablerecruiting
NCT05775796
Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)treatment2recruiting
NCT03066986
Study of Sting Challenge and Serological Responses to Jack Jumper Venom Immunotherapy With Inulin as Adjuvant (Jumpvax)treatment1 / 2unknown_status
NCT03722186
Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced MalignanciesNo drug interventionstreatment1suspended
NCT06429839
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patientstreatment2recruiting
NCT04405622
Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.treatment2active_not_recruiting
NCT03763630
MAPS & ITEC Cohorts: 6-8 Years Follow-upNo drug interventionsprevention2completed
NCT06020430
Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and ChemotherapyNo drug interventionstreatmentNot Availablerecruiting
NCT05652530
Clinical Study of the Safety and Efficacy of BCMA CAR-NKNo drug interventionstreatment0recruiting
NCT05690048
Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)treatment2not_yet_recruiting
NCT05218148
SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinomatreatment2not_yet_recruiting
NCT06521866
Toripalimab Combined With Targeted Therapy and Chemotherapy With or Without Radiotherapy as First-Line Treatment for Advanced Colorectal Cancertreatment2not_yet_recruiting
NCT05024266
Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinomatreatment2unknown_status
NCT05311566
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancertreatment2recruiting
NCT05435365
Investigating The Experiences of Patients In Immunotherapy Clinical TrialsNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT03563482
Correlation of Metabolic Imaging With Immune Markers in NSCLC Candidate to Immunotherapy.No drug interventionsdiagnosticNot Availableunknown_status
NCT05652673
Safe Stop Ipilimumab-nivolumab (IPI-NIVO) TrialtreatmentNot Availablerecruiting
NCT04807127
A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint BlockadeNot AvailableNot Availablerecruiting
NCT06120127
Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrencetreatment2recruiting
NCT06421376
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal CancerNo drug interventionstreatment2recruiting
NCT02968394
Omalizumab Treatment in Venom Immunotherapy With Systemic ReactionstreatmentNot Availableunknown_status
NCT05657262
Effect of Z Technıque on Pain, Comfort, Symptoms in Ummunotherapy AreasNo drug interventionshealth_services_researchNot Availablecompleted
NCT04037462
Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapytreatment1 / 2terminated
NCT06461780
Exploring Physical and Psychological Needs and Quality of Life in Patients With Advanced Cancer Receiving ImmunotherapyNo drug interventionsscreeningNot Availablerecruiting
NCT05034289
Promoting INformed Approaches in Precision Oncology and ImmuNoTherapyNo drug interventionshealth_services_researchNot Availablecompleted
NCT05479240
Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancertreatment2not_yet_recruiting
NCT06378840
the Predictive Value of Immune Cell in Locally Advanced Cervical CancerNo drug interventionsNot AvailableNot Availablerecruiting
NCT05493267
A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TBtreatment4recruiting
NCT04169867
Polish Microbiome MapNot AvailableNot Availableunknown_status
NCT01256801
Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural EffusionNo drug interventionsNot AvailableNot Availablecompleted
NCT06218901
Association of Psychological Distress in Patients With Lung CancerNo drug interventionsNot AvailableNot Availablerecruiting
NCT04045301
Omalizumab to Accelerate a Symptom-driven Multi-food OITtreatment2recruiting
NCT05314101
TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancertreatment2unknown_status
NCT05136768
Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC)treatment2not_yet_recruiting
NCT05487469
Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary BypasspreventionNot Availableunknown_status
NCT05304546
Overcoming Primary Resistance to Immunotherapy in Metastatic Melanomatreatment2not_yet_recruiting
NCT05321212
Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH)No drug interventionsNot AvailableNot Availablecompleted
NCT04682210
Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resectiontreatment3not_yet_recruiting
NCT05387681
Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced Gastrictreatment2not_yet_recruiting
NCT06262581
Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgerytreatment2recruiting
NCT05460195
Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluationtreatment2recruiting
NCT05025514
Retrospective Study of COVID-19 Vaccines in Patients Undergoing Immunotherapy for Cancer.No drug interventionsNot AvailableNot Availableunknown_status
NCT04807114
A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLCNot AvailableNot Availablerecruiting
NCT05202314
Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic CancertreatmentNot Availablerecruiting
NCT03971214
PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancertreatment1unknown_status
NCT00540150
Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific ImmunotherapyNo drug interventionstreatment3completed
NCT06313450
De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal CarcinomaNo drug interventionstreatmentNot Availablerecruiting
NCT06125223
PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell CarcinomaNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT05669638
A Prospective Study to Observe Adverse Effects in Patients Receiving Anti-PD1 ImmunotherapyNo drug interventionsNot AvailableNot Availablerecruiting
NCT06093438
Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancertreatment1 / 2recruiting
NCT05825443
Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patientstreatment2recruiting
NCT04284332
Phase II Prospective Study of Bintrafusp Alfa in Previously Treated Patients With Recurrent and Metastatic (R/M) Non-keratinizing Nasopharyngeal Carcinoma (NPC)treatment2not_yet_recruiting